SF 332 — A bill for an act making changes to the controlled substance schedules, and providing penalties, and including effective date provisions. (Formerly SSB 1085.) Effective 4-7-17.

Senate File 332 - IntroducedEnrolled SENATESenate FILEFile 332 BYAN COMMITTEEACT ONMAKING JUDICIARYCHANGES (SUCCESSOR TO SSBTHE 1085)CONTROLLED ASUBSTANCE BILLSCHEDULES, FORAND AnPROVIDING ActPENALTIES, makingAND changesINCLUDING toEFFECTIVE theDATE controlledPROVISIONS. substance schedules, and providing penalties, and including effective date provisions.

TLSBDIVISION 1287SVI (2)CONTROLLED 87SUBSTANCES jm/nhSection S.F.1.

332 DIVISION I CONTROLLED SUBSTANCES Section 1.

NEW PARAGRAPH.PARAGRAPH .

3,4-Dichloro-N-[2- (dimethylamino)cyclohexyl]-N-methylbenzamide, its isomers, esters,Senate ethers,File salts332, andp. salts of isomers, esters and ethers.

2 esters, ethers, salts and salts of isomers, esters and ethers.

Decocainized coca leaves or LSBextractions 1287SVof (2)coca 87leaves, -1-which jm/nhextractions 1/5do S.F.not contain cocaine or ecgonine, are excluded from this paragraph.

332The extractionsfollowing substances and their salts, optical and geometric isomers, derivatives, and salts of cocaderivatives leaves,and whichoptical extractionsand dogeometric notisomers containincluding cocaine and ecgonine and their salts, isomers, derivatives and salts of isomers and derivatives, and any salt, compound, derivative, or ecgonine,preparation thereof that is chemically equivalent or identical to any of such substances, are excludedincluded fromin this paragraph.paragraph except that the substances shall not include :

The following substances and their salts, optical and geometric isomers, derivatives, and salts of derivatives and optical and geometric isomers including cocaine and ecgonine and their salts, isomers, derivatives and salts of isomers and derivatives, and any salt, compound, derivative, or preparation thereof that is chemically equivalent or identical to any of such substances, are included in this paragraph except that the substances shall not include:

Section 124.210, subsection 3, Code 2017, is amended bySenate addingFile the332, followingp. new paragraphs:

3 by adding the following new paragraphs:

LSBSec. 1287SV (2) 87 -2- jm/nh 2/5 S.F.

332 Sec.

EXPLANATION______________________________ The______________________________ inclusionJACK ofWHITVER thisLINDA explanationUPMEYER doesPresident notof constitutethe agreementSenate withSpeaker of the explanation’sHouse substanceI byhereby thecertify membersthat ofthis bill originated in the generalSenate assembly.and is known as Senate File 332, Eighty-seventh General Assembly.

This______________________________ billW. makes changes to the controlled substance schedules and modifies the regulation of precursor substances.

DIVISIONCHARLES ISMITHSON ——Secretary CONTROLLEDof SUBSTANCES.the Senate Approved _______________, 2017 ______________________________ TERRY E.

TheBRANSTAD billGovernor classifies four synthetic opioids as schedule I controlled substances in conformance with scheduling actions taken by the United States department of justice, drug enforcement administration.

The bill also classifies as a schedule I controlled substance a micro-opioid receptor agonist with analgesic activity similar to morphine.

The bill classifies thiafentanil, an opioid and analogue of fentanyl, as a schedule II controlled substance.

The bill removes hydrocodone-combination products from the list of substances classified as schedule III controlled substances.

Currently, hydrocodone, as a single-entity substance, is classified as a schedule II controlled substance.

The change under the bill effectively makes all hydrocodone-containing products subject to the controls, security, reporting, and penalty provisions for schedule II controlled substances.

The bill removes naloxegol, a new molecular entity and derivative of naloxone, from control as a schedule III controlled substance.

The federal food and drug administration approved naloxegol for the treatment of opioid-induced LSB 1287SV (2) 87 -3- jm/nh 3/5 S.F.

332 constipation in adults with chronic non-cancer pain.

The bill also removes [\123\I]ioflupane from control as a schedule II controlled substance.

This substance is a new molecular entity and is the active pharmaceutical ingredient in the drug DaTscan, approved by the federal food and drug administration for use in diagnosis of patients suspected of having Parkinson’s disease.

The bill classifies the substance commonly known as tramadol, a centrally acting opioid analgesic, as a schedule IV controlled substance.

This substance was previously marketed and distributed as a noncontrolled prescription drug.

Effective August 18, 2014, the federal drug enforcement administration classified tramadol as a schedule IV controlled substance under federal law.

The bill classifies alfaxalone, a neurosteroid with central nervous system depressant properties, as a schedule IV controlled substance.

The federal food and drug administration approved this intravenous injectable anesthetic for use by or on the order of a licensed veterinarian.

Alfaxalone is not available by prescription and is approved for use in veterinary practice.

The bill classifies suvorexant, an insomnia treatment approved by the federal food and drug administration, as a schedule IV controlled substance.

This is a novel, first-in-class, chemical substance and information on actual abuse data is not available.

However, data from clinical studies supports the classification in schedule IV.

The bill classifies eluxadoline, a new entity with central nervous system opioid properties approved by the federal food and drug administration for the treatment of irritable bowel syndrome with diarrhea, as a schedule IV controlled substance.

The bill classifies brivaracetam, also known as briviact or BRV, as a schedule V controlled substance.

Briviact is a new molecular entity with central nervous system depressant properties and has been approved as an add-on treatment to LSB 1287SV (2) 87 -4- jm/nh 4/5 S.F.

332 other medications to treat partial onset seizures in patients age 16 years and older with epilepsy.